Newsletter | November 22, 2019

11.22.19 -- How To Intensify And Accelerate Your Bioprocess

 

How To Intensify And Accelerate Your Bioprocess

Continuous processing in biomanufacturing has the potential to increase production capacity, reduce costs, and improve biopharmaceutical product quality. Read the articles below to learn more about the technologies that can enable continuous production throughout your process.

Integrated Tools For Upstream Process Intensification: Part I
 

Changes to bioprocessing methodologies in the biopharmaceutical industry are being driven by the need for increased speed, a lower cost of goods (COGs), and greater flexibility. Faster development times are required to progress biologics and vaccines more rapidly into clinical development and then to market to improve worldwide accessibility.

Integrated Tools For Upstream Process Intensification: Part II
 

Continue reading part two of this series to learn how leveraging integrated upstream and downstream technologies will help the biopharmaceutical industry to achieve process intensification. This could potentially accelerate manufacturing speed and productivity by using smaller facilities and fewer resources to deliver better global access to more affordable biologics and vaccines.

Single-Use Systems For Vaccine Manufacturing
 

In order to meet global demand, it is predicted that next-generation vaccines will be based on recombinant approaches and be produced in intensified single-use systems (SUS) to increase capacity at reduced costs. However, despite their benefits, SUS for vaccine manufacturing face a number of key regulatory challenges, which require greater reliance by the biopharmaceutical industry on SUS suppliers. 

Single-Use Platforms Accelerate Viral Vaccine Development And Manufacturing
 

The vaccine industry requires new tools to help bring its pipeline of new products to the market quickly, safely, and economically. Learn how one company is exploring the best ways of implementing single-use platforms for next-generation vaccines that avoid reinventing the wheel for each candidate, thereby reducing time-to-market, lowering production costs, lowering risks, and increasing flexibility.